The biomedical model of ketamine treatment focuses on neurobiological effects to address neurochemical and structural deficits, frames dissociation as an adverse effect, minimizes the importance of "set and setting," and utilizes subanesthetic dosages of 0.5–1.0 mg/kg without accompaniment.

Authors

• Person: Not available Organization: Frontiers in Psychiatry
  The Montreal model: an integrative biomedical-psychedelic ...

Sources

• The Montreal model: an integrative biomedical-psychedelic ... www.frontiersin.org Frontiers in Psychiatry via serper

Referenced by nodes (1)

• set and setting concept